Gamma Delta T Cell Therapy Represents One of the Most Promising T Cell Therapies in Clinical Development

Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Gamma Delta T Cell Cancer Therapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering.

The introduction of T cell-based immunotherapy has greatly revolutionized the paradigm of cancer treatment. The progress in clinical research and innovation has led to the identification of small subsets of T cells classified as gamma delta T cells. Gamma delta T cells are the minor subsets of T cells that constitutes only about 1% to 5% of T cell population. Their unique biology and conferred advantages over conventional T cells have enabled the researchers to utilize these novel cells as a promising candidate for adoptive immunotherapy. Since its identification, scientists have harnessed the potential of gamma delta T cells in the management of several cancers.

The gamma delta T cell therapy represents one of the most promising T cell therapies in clinical development which can be suggested by the rapid research and development activities among the pharmaceutical companies. The major companies in the market are presenting promising preclinical and clinical data of gamma delta T cell therapies. For instance, in 2022, In8bio provided an update on ongoing phase-I clinical trial of INB-200. The novel gamma delta T cell product has shown a manageable safety profile and promising progression-free survival and overall survival rate. The encouraging data from a clinical trial suggest the promising future of gamma delta T cell therapy in the management of cancer.

Apart from cancer, researchers are also expanding the role of gamma delta T cell therapy in the management of other diseases such as HIV, COVID-19, and other viral infections. Recently, Enochian Biosciences announced that US FDA has accepted a pre-investigational new drug request for a cell therapy treatment that combines autologous natural killer and gamma delta T-cells. Furthermore, several preclinical studies also indicate an innate involvement of gamma delta T cells in viral infections. The coming years will witness the translation of these investigations into clinical trials, which will further propel the growth of market.

The rising investment from the pharmaceutical giants have led to the development of a strong clinical pipeline of gamma delta T cell therapy products. The key players operating in the market are Acopedia, Takeda Pharma, Lava Therapeutics, TC Biopharma, Cytomed Therapeutics, Gamma Delta Therapeutics, and Adapate Therapeutics. The major drugs in the clinical pipeline include INB-200, LAVA-051, ADI-001, TCB-007, ACE-1813, KB-PD1, and several others. Apart from this, several pharmaceutical giants have also entered into a collaboration, mergers, or other alliances to maintain their position in the market. In January 2022, Takeda Pharmaceutical announced the exercise of its option to acquire Adapate Therapeutics. Through this acquisition, Takeda will obtain Adapate antibody-based gamma delta T-cell engager platform including pre-clinical candidate and discovery pipeline programs.

US is currently dominating the global initiatives in the development of gamma delta T cell therapy driven by a large number of ongoing clinical trials, presence of key players in the region, and increasing initiatives from various stakeholders in the industry. Apart from this, US FDA is also granting orphan drug designation to gamma T cell therapies which provides several financial and non-financial incentives to boost the drug development process. For instance, in 2021, US FDA granted orphan drug designation to two gamma delta T cell therapies including GDX012 for acute myeloid leukemia and LAVA-051 for chronic lymphocytic leukemia.

The global gamma delta T-cell therapy market is expected to surpass US$ 4 Million by 2028. The rise in cancer rates and the subsequent unavailability of effectively curing drugs will propel the growth of the market in the coming years. In addition, new product launches, continuous investment by pharmaceutical companies, and increasing government initiatives will also contribute in growth of market. The report provides a comprehensive analysis of the ongoing clinical trials in gamma delta T cell therapy. By analyzing the market dynamics, the future market opportunity of gamma delta T cell therapy in various cancers is also forecasted.

The report highlights include:

• Commercialization Market Potential After Market Launch: > USD 4 Billion
• Insight on Key Drugs In Research & Development
• Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
• Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies
• Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
• Adopted Approaches for Gamma Delta T Cell Therapy

Company Profiles:

• Acepodia
• Adaptate Therapeutics
• Adicet
• Cytomed Therapeutics
• Gadeta
• GammaDelta Therapeutics
• IN8bio
• Kiromic Biopharma
• Lava Therapeutics
• Takeda Pharmaceuticals
• TC Biopharm

For more information about this report visit https://www.researchandmarkets.com/r/4ixj7r

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900